A double-blind clinical trial of kamalahar, an indigenous compound preparation, in acute viral hepatitis.
Kamalahar is an indigenous preparation reported to be beneficial in acute viral hepatitis. To evaluate the efficacy of Kamalahain acute viral hepatitis in a double-blind, placebo-controlled study. Fifty two patients with acute viral hepatitis were randomized to receive either Kamalahar 500 mg or a matched placebo three times a day for 15 days. Forty four patients (Kamalahar 20; placebo 24) completed the trial. Improvement in clinical signs was more marked with Kamalahar compared to placebo. The fall in serum bilirubin (p < 0.001), SGPT (p < 0.001) and serum alkaline phosphatase (p < 0.005) at day 15 was significantly greater with the drug. No significant side effects were observed. Kamalahar offers therapeutic promise in acute viral hepatitis.